Live Q&A: Right Patient, Right Treatment, Right Time: Utilizing Early, High-Efficacy Therapies to Improve Outcomes in RRMS

Hitting the Target with IL-23 Inhibitors in Psoriatic Arthritis is organized by CME Outfitters, LLC.

Premiere Date: Tuesday, October 13, 2020
Credit Expiration Date: Wednesday, October 13, 2021

Target Audience
Neurologists, MS specialists, PAs, nurse practitioners, nurses, and pharmacists

This activity offers CE credit for:
• Pharmacists (ACPE)
• Pharmacists (ACPE)
• Other

Statement of Need:
Recent studies have demonstrated the benefits of early and aggressive treatment strategies in reducing disability progression and the frequency of relapses in patients with relapsing-remitting multiple sclerosis (RRMS), marking a paradigm shift in the treatment of patients with RRMS. The traditional escalation approach is now often set aside in favor of the more individualized "induction" approach, which utilizes "early and aggressive" treatment with high-efficacy disease-modifying therapies (DMTs) to treat patients with high-risk disease.

The induction approach requires selection of DMTs based on disease activity, prognostic factors, and patient characteristics. This is challenging for clinicians due to the expanding treatment landscape for RRMS and the lack of specific guidelines. Additionally, neurologists often lack the knowledge and competence to identify patients who are candidates for this approach.

This live question and answer session is your opportunity to ask questions based on the CME Outfitters virtual symposium where expert faculty focused on the prognostic factors that should be considered when developing treatment plans for patients with MS, as well as the latest clinical data on approved and emerging DMTs.

Learning Objectives:
At the end of this CE activity, participants should be able to:
• Select patients with RRMS who are likely to benefit from early treatment with high-efficacy DMTs.
• Develop tailored treatment approaches based on individual patient characteristics.
• Apply the latest clinical data on approved and emerging DMTs in monitoring treatment response, safety, and tolerability.

The following learning objectives pertain only to those requesting CNE or CPE credit:
• Describe patients with RRMS who are likely to benefit from early treatment with high-efficacy DMTs.
• Summarize a tailored treatment approach based on individual patient characteristics.
• Explain the latest clinical data on approved and emerging DMTs in monitoring treatment response, safety, and tolerability.